albumin zone usually contains less than 5%o damaged components.
During incubation with immune or nonimmune plasma a fraction of the purified HGH-I... becomes damaged ("incubation damage"). This phenomenon is characterized by the appearance of labeled fragments that bind nonspecifically to certain plasma proteins, primarily a-and ,8-globulins, and by the release of a small amount of P"' as iodide. Similar observations have been reported with insulin-I.3' (10) . Binding of damaged fractions to a-and ,8-globulins cannot be reversed by the addition of high concentrations of unlabeled HGH and is relatively unaffected by the presence of moderately high concentrations of HGH at onset of incubation. The factors responsible for damage are not known, but the addition of diisopropyl fluorophosphate (to inhibit enzymatic activity in plasma) is ineffective in preventing damage. HGH contains disulfide groups which might be subject to reductive splitting by -SH groups in plasma, a process previously suggested as a cause of damage to insulin-I"3' in plasma (11) .
Plasma to be tested for the presence of antibody was diluted 1: 5 in Veronal buffer (0.1 M, pH 8.6) containing human serum albumin (5 mg per ml) and incubated with a tracer quantity of HGH-I"' (HGH concentration, approximately 1 m~ug per ml) for 4 to 10 days at 4°C. To separate antibody-bound HGH-I'3' from free (unbound) HGH-I'31, samples of the incubation mixtures were applied to DEAE paper strips for chromatoelectrophoresis (10) (Veronal buffer, 0.1 M, pH 8.6 at 500 v for 2 hours) or to Whatman 3MM filter paper for electrophoresis (Veronal buffer, 0.025 M, pH 8.6, at 600 v for 6 hours). The strips were dried in an oven and scanned for radioactivity in an automatic strip counter. In both systems described, free HGH-I... is adsorbed to the paper at the site of application, whereas HGH-I3' bound to antibody migrates with the 'y-or inter 8--y-globulins. The binding capacity of plasma antibodies for HGH was evaluated by a method similar to that described for insulin (10) body. The B/F ratio was plotted as a function of unlabeled hormone bound. Extrapolation of the curve to a B/F ratio of zero yields the binding capacity.
Incubated mixtures of plasma and HGH-I1" with or without added unlabeled HGH were analyzed by immunodiffusion (13) and microimmunoelectrophoresis (14) in agar gel. The challenging antisera were horse or rabbit antihuman whole serum or rabbit antihuman y-globulin. After the development of visible precipitin bands the slides were dried, radioautographed, and stained with amido black.
For immunoprecipitation experiments in test tubes (15) , rabbit antihuman -y-globulin in marked excess was added to previously incubated mixtures of plasma and HGH-I"' (with or without added unlabeled HGH). After further incubation at room temperature for 2 hours, and then at 40 C for 18 hours, the mixtures were centrifuged; the supernatant solution was removed, and the precipitates were resuspended and washed with cold normal saline. Precipitates, supernatant solutions, and washes were assayed separately for radioactivity in a well scintillation counter.
Results
In the two adults without known pituitary disease, the repeated parenteral administration of HGH was associated, within 30 to 60 days, with the appearance in plasma of a y-or inter /3-yglobulin that binds HGH-I131 (Figures 1 and 2 ). Cessation of therapy resulted in a slow fall, and resumption of therapy was followed by a rapid rise in concentration of this HGH-binding globulin.1 HGH-binding globulins were also detected in the plasma from three of four children who had been treated with HGH for prolonged periods of time for retarded growth ( Figure 3 , Table I ). In none of several hundred patients not treated with HGH was antibody detectable by chromatoelectrophoresis or electrophoresis on paper.
Immunodiffusion and microimmunoelectrophore- (Table II) . That more than 50% of the tracer HGH-1131 was not precipitated in this system is due to the addition of a large volume of antihuman y-globulin to produce precipitation, 
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which resulted in dilution of the HGH-anti-HGH complexes and dissociation of HGH from its antibody before precipitation by anti-antibody. In all the systems used, the binding of HGH-I131 to the -y-globulins was readily inhibited, competitively and specifically, by the addition of unlabeled hormone (Figures 4, 5, and 6 ; Table II) .
In contrast, the nonspecific binding of damaged HGH-I'31 to plasma proteins, particularly a-and ,8-globulins, as determined by paper chromatoelectrophoresis or agar gel immunoelectrophoresis, Uwas not affected by the presence of an excess of unlabeled HGH. Dissociation of HGH-13' from antibody occurred rapidly when the antibody concentration was decreased ten times by dilution, and when a large excess of unlabeled HGH was added to a mixture of HGH-I13' and antibody (Figure 7) , suggesting that the antibodies bound HGH with a weak energy.
Peak HGH-binding capacities in the two adult subjects were 0.3 ug per ml (C. D.) ( Figure 6 ) and 0. (22) found antibodies in one of seven treated subjects. However, the hemagglutination method is subject to falsely positive reactions and cannot be relied upon for evidence of specific antibody to a single substance, since the method does not identify the antigen and antibody responsible for the reaction. For example, a small contaminant, present even at less than 1%o of the content of the immunizing preparation, if potently antigenic, might induce the formation of antibodies capable of completely agglutinating the tanned red cells exposed to the antigenic mixture and therefore coated with both HGH and contaminant. In contrast, the HGH-I13' method allows specific identification of the antigen reacting with the antibody. Once it has been shown that a significant percentage of the labeled material is HGH (23), the demonstration that the bulk of labeled material is bound to antibody clearly reveals the presence of antibodies specific for HGH. In general, techniques utilizing radioisotopically labeled hormone afford greater specificity and sensitivity than other methods for demonstrating both precipitating and nonprecipitating antibody.
The formation of antibody to human growth hormone in normal human subjects suggests one of two possibilities: 1) Some structural difference may exist between the administered hormone and the endogenous circulating hormone, or 2) no such difference exists, but during extraction and purification a small fraction of the administered preparation of hormone was altered and thereby endowed with an antigenic potency not present in the native molecule.
With reference to the first of these alternatives a structural difference may be present for one of several reasons. HGH as it exists in the pituitary gland may be different from the hormone that is released into the blood. Pituitary HGH, like thyroglobulin, may not be a normal plasma constituent and therefore might be antigenic. Alternatively, the chemical methods used in the storage of pituitary glands and in the extraction and purification of hormones may produce molecular modifications. Experiments in which circulating hormone was compared with extracted pituitary hormone by a quantitative immunochemical procedure using rabbit antibodies to HGH (23) provide no evidence that the administered hormone differs significantly from the endogenous circulating hormone. Extracted pituitary hormone and endogenous plasma hormone reacted identically (23) Other potential effects of HGH antibodies in man remain to be assessed. Whereas, in the absence of endogenous HGH secretion, the only concern is the possible development of resistance to therapy, the possibility of antigen-antibody reactions within the cells of the anterior pituitary in persons with residual potential secretion of HGH must be considered but not necessarily feared. The almost universal development of insulin antibodies in persons treated with insulin (10) (human insulin has been shown to react with such antibodies) (11, 30) has not only failed to produce drastic effects (except for relatively infrequent cases of insulin allergy and insulin resistance) but is also compatible with persistent excellent insulin-secretory activity (31) .
The virtual disappearance of HGH antibody after discontinuation of HGH therapy in one of the normal subjects studied here suggests that a brief immunization period need not result in the permanent production of antibody. This observation suggests also that endogenous plasma HGH secretion (which presumably remained unimpaired after antibody formation) did not continue the antigenic stimulus. The consequences of much more prolonged courses of therapy merit independent evaluation. Summary 1) Antibodies to human growth hormone (HGH) in human subjects treated with HGH were demonstrated by incubation of plasma with HGH-I31' and separation of antibody-bound and free HGH by chromatoelectrophoresis and electrophoresis on paper. The existence of antibodies was confirmed by immunodiffusion and immunoelectrophoresis on agar gel and by immunoprecipitation with rabbit antihuman gamma globulin.
2) HGH-binding capacities as high as 4 pg per ml of plasma were observed.
3) The nature of HGH antigenicity in man is considered, and several possible explanations are discussed. Addendum Since the preparation of this manuscript, J. L. Touber, using I"3-labeled HGH, also reports (personal communication) antibodies to HGH, detected on agar gel electrophoresis, in one of Prader's cases (29) treated with HGH.
